Eli Lilly and Company
As of Oct 23, 2026 close
- Market cap
- $1.14T
- P/E (TTM)
- 42.61
- Forward P/E
- 22.66
- Dividend yield
- 0.51%
- 52-week range
- $793.82$1,311.75
- Volume (live)
- -
- Avg. volume (3M)
- 2.31M
Eli Lilly and Company (LLY) Stock Price & Financial Analysis
Eli Lilly and Company Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1,257.62 - $1,307.92 |
|---|---|
| 52-Week High | $1,311.75 |
| 52-Week Low | $793.82 |
| Open | $1,304.15 |
| Volume (last close) | 2.28M |
| Average Volume (3M) | 2.31M |
| Revenue (TTM) | 79.67B |
|---|---|
| Net Income (TTM) | 26.71B |
| Free Cash Flow (TTM) | 20.05B |
| EPS (TTM) | $29.79 |
| Profit Margin | 33.53% |
| Operating Margin | 49.72% |
| Return on Equity (ROE) | 78.84% |
| Debt to Equity | 1.62 |
| Annual Dividend | $6.69 |
|---|---|
| Dividend Yield | 0.51% |
| Payout Ratio | 22.46% |
| Last Dividend Ex-Date | Aug 14, 2026 |
| Market Cap | 1.14T |
|---|---|
| Shares Outstanding | 893.70M |
| P/E Ratio (TTM) | 42.61 |
| Forward P/E | 22.66 |
| Price to Sales (P/S) | 14.29 |
| Price to Book (P/B) | 33.59 |
| EV/EBITDA | 28.03 |
| 50-Day MA | $1,182.47 |
|---|---|
| 200-Day MA | $1,081.75 |
| 1-Year Change | +59.15% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Eli Lilly and Company at a Glance
As of the Oct 23, 2026 close, Eli Lilly and Company (LLY) has a market capitalization of $1.14T. The stock trades at 42.6× trailing earnings, 22.7× forward earnings and 14.3× sales. Over the trailing twelve months it earned $26.71B on revenue of $79.67B (a 33.5% profit margin) and generated $20.05B of free cash flow. Revenue grew 49.6% year over year.
As of its latest reported balance sheet, it holds $8.89B in cash and securities against $54.91B of debt, a net debt position of $46.02B.
Eli Lilly and Company pays a quarterly dividend totaling $6.69 per share a year, a 0.51% yield at the Oct 23, 2026 close, with a 22% payout ratio and 11 consecutive years of dividend increases.
The share price is up 59.2% over the past year. At $1273.46 (the Oct 23, 2026 close) it sits near the top of its 52-week range of $793.82 to $1311.75, above its 200-day moving average of $1081.75.
Based on 31 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $1368.33, 7.4% above the Oct 23, 2026 close.
Frequently Asked Questions About Eli Lilly and Company
What is the current stock price for LLY?
As of the Oct 23, 2026 close, LLY stock trades at $1273.46. The 52-week range is $793.82–$1,311.75, with a day range of $1257.62–$1307.92.
What is the P/E ratio for LLY?
As of the Oct 23, 2026 close, Eli Lilly and Company's trailing twelve-month (TTM) P/E ratio is 42.6, meaning investors pay $42.6 for every $1 of annual earnings. The forward P/E is 22.7, reflecting analyst expectations for future earnings. Eli Lilly and Company operates in the Healthcare sector.
Does LLY pay dividends?
Yes, Eli Lilly and Company pays a 0.51% annual dividend yield as of the Oct 23, 2026 close ($6.69 per share a year). The trailing twelve-month payout ratio is 22.5%. The most recent ex-dividend date was August 14, 2026.
What do analysts recommend for LLY?
Based on ratings from 31 professional analysts over the last 90 days, the consensus for LLY is Buy. The average 12-month price target is $1368.33, a 7.4% upside from the Oct 23, 2026 close of $1273.46.
What is the market cap of LLY?
As of the Oct 23, 2026 close, Eli Lilly and Company's market capitalization is $1.14T, classifying it as a mega-cap company. Eli Lilly and Company operates in the Healthcare sector within the Drug Manufacturers - General industry.